Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Cost analysis of prescribing analogue insulin should take into account the bigger picture of diabetes treatment prescribing cost
    • Iskandar Idris, Consultant Diabetologist and Honorary Associate Professor
    • Other Contributors:
      • Bryan Hucknall, Mohamed Roshan, Melanie Davies on behalf of the East Midlands SHA Diabetes QIPP WorkStream steering group

    Dear Editor,

    We read with interest the article 'Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin'(1). The stated aim of this study was to characterize the pattern of insulin prescriptions dispensed between 2000 and 2009 in UK and to evaluate the financial cost to the National Health Service (NHS) of using analogue insulin instead of its equivalent human insulin p...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Letter to the editor

    Dear Editor of BMJ open,

    last week I read the above mentioned article by Holden et al. and I was quite astonished. The authors write (page 5-6) "The purpose of this study was to calculate a monetary value to raise awareness of the cost implications (...) rather than to suggest an exact percentage of patients with diabetes who could be equally well treated with human insulin instead of analogue insulin." In other...

    Show More
    Conflict of Interest:
    None declared.